India’s small and medium-sized pharma manufacturers are set to face tighter regulatory scrutiny, with the Central Drugs Standard Control Organisation (CDSCO) directing state authorities to conduct inspections under the revised Schedule M manufacturing norms. The move marks the end...
A high-level government panel has urged the cancellation, suspension, and deferment of Quality Control Orders (QCOs) covering more than 200 products, warning that the expanding scope of mandatory standards has increased compliance costs for manufacturers, disrupted supply chains, and...
